David A. Barbie

Oncology
450 Brookline Ave
Boston, MA 02215

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 141 publications

Polycomb Scaffolding Subunit EED Supports the SCLC Neuroendocrine Identity and EGFR-Mutant LUAD to SCLC Transformation.

Polycomb Scaffolding Subunit EED Supports the SCLC Neuroendocrine Identity and EGFR-Mutant LUAD to SCLC Transformation.

Journal: The Journal of clinical investigation
Published: August 18, 2026

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 24, 2026

Degrading TBK1 to disarm VHL-deficient renal cancer.

Degrading TBK1 to disarm VHL-deficient renal cancer.

Journal: Cell chemical biology
Published: March 19, 2026

MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies.

MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 02, 2026

MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.

MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 02, 2026

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 18, 2026

Integrin beta-6: Its emerging role as a therapeutic target in solid tumors.

Integrin beta-6: Its emerging role as a therapeutic target in solid tumors.

Journal: Cancer treatment reviews
Published: December 22, 2025

Cancers modulate p53 truncal neoantigen display to evade T cell detection.

Cancers modulate p53 truncal neoantigen display to evade T cell detection.

Journal: bioRxiv : the preprint server for biology
Published: December 15, 2025

Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.

Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.

Journal: JCO precision oncology
Published: December 05, 2025

Polyelectrolyte nanoparticles enable intracellular delivery of STING protein fragments for ovarian cancer immunotherapy.

Polyelectrolyte nanoparticles enable intracellular delivery of STING protein fragments for ovarian cancer immunotherapy.

Journal: Materials today. Bio
Published: December 03, 2025

Targeting STING to generate therapeutic anti-tumor immunity.

Targeting STING to generate therapeutic anti-tumor immunity.

Journal: Cancer cell
Published: September 22, 2025

Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8+ and PD-1+ Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors.

Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8+ and PD-1+ Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors.

Journal: JCO precision oncology
Published: September 04, 2025
Showing 1-12 of 141

Last Updated: 09/26/2026